We are a nuclear medicine technology company committed to providing the United States with stable, domestic and environmentally friendly radioisotope supply solutions to meet the needs of patients and advance clinical research. Our innovative technologies have the ability to fundamentally transform the ways that medical radioisotopes are produced and distributed around the world.
– Approval enables expanded manufacturing capacity and supports commercial launch of RadioGenix Systems to produce critically important diagnostic imaging radioisotope technetium-99m from domestic, non-uranium based molybdenum-99 – BELOIT, Wis.
BELOIT, Wis. – June 19, 2018 – NorthStar Medical Radioisotopes, LLC (NorthStar), a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in a panel session on molybdenum-99 (Mo-99) supply at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI), from June 23 – 26, 2018, in Philadelphia, Pa.
BELOIT, Wis. – June 18, 2018 – NorthStar Medical Technologies (NorthStar), a company involved in the development, production and distribution of radioisotopes for medical imaging and therapeutics, today provided a progress update on its actinium-225 (Ac-225) radioisotope program.
Questions about company, products, supply solutions, careers or anything else?